Taken together, these results imply that mass spectrometry methods for p-tau detection, specifically p-tau217, may have strong future roles in AD detection and prognosis, edging out older immunoassay methods in terms of predictive value and accuracy. The gene discussed is MAPT; the disease is Alzheimer disease.